Online Table 5:
Multivariate predictors of MACE in statin strength analysis by terciles
| aSHR (95% CI) | p Value | |
|---|---|---|
| Statin strength | 0.0012 | |
| None (Reference) | - | |
| 1st tercile | 0.74 (0.53–1.03) | |
| 2nd tercile | 0.61 (0.43–0.88) | |
| 3rd tercile | 0.45 (0.29–0.70) | |
| CAC Group | <0.0001 | |
| 0 (Reference) | - | |
| 1–100 | 1.02 (0.67–1.56) | |
| 101–400 | 4.11 (2.42–6.95) | |
| > 400 | 4.80 (2.50–9.23) | |
| Age (per 10 year increase) | 1.63 (1.45–1.84) | <0.0001 |
| Beta-blocker* | 1.54 (1.16–2.04) | 0.0029 |
| Hyperlipidemia* | 1.69 (1.36–2.10) | <0.0001 |
| Tobacco* | 1.75 (1.35–2.39) | <0.0001 |
| Year of CAC (per 1 year increase) | 0.92 (0.88–0.97) | 0.037 |
| ACE or ARB* | 1.21 (0.93–1.56) | 0.16 |
| Aspirin* | 0.93 (0.73–1.17) | 0.53 |
| Male sex | 1.19 (0.97–1.47) | 0.096 |
| Hypertension* | 1.03 (0.81–1.32) | 0.81 |
| Diabetes Mellitus* | 1.00 (0.74–1.36) | 0.98 |
| Charlton Comorbidity Score* | 1.13 (0.86–1.47) | 0.39 |
aSHR – adjusted subhazard ratio. MACE –Major adverse cardiovascular event. CAC – Coronary artery calcium.
Multivariable predictors of MACE in Cox proportional hazards model treating the strength of statin as a time-dependent variable.
*
Risk factors, beta-blockers, aspirin, and ACE-I or ARB use assessed at baseline.